Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | TPSAB1 | Q15661 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MME | P08473 | 1/20 | 0.43 |
| ▸ | ECE1 | P42892 | 1/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.42 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.40 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16384724 | 0.94 | SMN1; SMN2 (0.54) | SMN1; SMN2TPSAB1LMNAMMEECE1 | |
| SCHEMBL19706959 | 0.90 | SMN1; SMN2 (0.51) | SMN1; SMN2TPSAB1MMEECE1SIRT2 | |
| SCHEMBL21422716 | 0.88 | SMN1; SMN2 (0.53) | SMN1; SMN2TPSAB1LMNAMMEECE1 | |
| SCHEMBL16385192 | 0.88 | SMN1; SMN2 (0.53) | SMN1; SMN2TPSAB1LMNAMMEECE1 | |
| SCHEMBL17804042 | 0.84 | SMN1; SMN2 (0.51) | SMN1; SMN2TPSAB1LMNAMMEECE1 | |
| SCHEMBL21422694 | 0.81 | SMN1; SMN2 (0.59) | SMN1; SMN2TPSAB1LMNAMMEECE1 | |
| SCHEMBL16384896 | 0.81 | SMN1; SMN2 (0.59) | SMN1; SMN2TPSAB1LMNAMMEECE1 | |
| SCHEMBL29437120 | 0.80 | SMN1; SMN2 (0.54) | SMN1; SMN2TPSAB1MMEECE1SIRT2 | |
| SCHEMBL10739937 | 0.79 | SMN1; SMN2 (0.56) | SMN1; SMN2MMEECE1CTSLCTSS | |
| SCHEMBL10746514 | 0.79 | SMN1; SMN2 (0.56) | SMN1; SMN2MMEECE1CTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975120-B2 | Site-specific chemoenzymatic protein modifications | NOVARTIS AG (CH) | 2021-04-13 | — | — | US | disclosed |
| EP-3613755-A1 | LYSINE-SPECIFIC CHEMOENZYMATIC PROTEIN MODIFICATIONS USING MICROBIAL TRANSGLUTAMINASE | Novartis AG (CH) | 2020-02-26 | — | — | EP | disclosed |
| US-20190300570-A1 | SITE-SPECIFIC CHEMOENZYMATIC PROTEIN MODIFICATIONS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2019-10-03 | — | — | US | disclosed |
| US-20160237116-A1 | SITE-SPECIFIC CHEMOENZYMATIC PROTEIN MODIFICATIONS | NOVARTIS AG | 2016-08-18 | — | — | US | disclosed |
| US-9359400-B2 | Site-specific chemoenzymatic protein modifications | NOVARTIS AG (CH) | 2016-06-07 | — | — | US | disclosed |
| WO-2015006728-A2 | SITE-SPECIFIC CHEMOENZYMATIC PROTEIN MODIFICATIONS | USERA AIMEE (US) | 2015-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300570-A1 | SITE-SPECIFIC CHEMOENZYMATIC PROTEIN MODIFICATIONS | PTMS, TGM3, TGM1 | SMN1; SMN2 4867/4885TPSAB1 539/4885LMNA 4444/4885 |
| US-20160237116-A1 | SITE-SPECIFIC CHEMOENZYMATIC PROTEIN MODIFICATIONS | PTMS, TGM3, TGM1 | SMN1; SMN2 4867/4885TPSAB1 539/4885LMNA 4444/4885 |
| US-10975120-B2 | Site-specific chemoenzymatic protein modifications | PTMS, TGM3, TGM1 | SMN1; SMN2 4867/4885TPSAB1 539/4885LMNA 4444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.